Biomarin Pharmaceutical

Biomarin Pharmaceutical

Yahoo Finance • last month

2 Profitable Stocks Worth Your Attention and 1 We Find Risky

2 Profitable Stocks Worth Your Attention and 1 We Find Risky Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn't mean it will thr... Full story

Yahoo Finance • last month

BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. BioMarin Pharmaceutical (NasdaqGS:BMRN) reported positive Phase 3 study results for VOXZOGO in children with hypochond... Full story

Yahoo Finance • last month

What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year

Key Points Krensavage bought 241,245 Ultragenyx Pharmaceutical shares last quarter. The quarter-end position value increased by $4.75 million, reflecting both trading and share price changes. The trade represented a roughly 2% increase in... Full story

Yahoo Finance • 2 months ago

1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to... Full story

Yahoo Finance • 2 months ago

BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best low priced stocks to buy for the next 3 years. On May 18, BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met only one of its two co-primary endp... Full story

Yahoo Finance • 2 months ago

StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Guggenheim upgraded StubHub (STUB) to... Full story

Yahoo Finance • 2 months ago

Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More

Quick Read: The trading week started mixed as many of the same issues we saw last Friday remained front and center on Monday. There is a rumbling in the bond market that new Federal Reserve Chairman Kevin Warsh may have to raise rates thi... Full story

Yahoo Finance • 2 months ago

BioMarin Pharmaceutical Enters Oversold Territory (BMRN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 2 months ago

BioMarin Pharmaceutical’s Q1 Earnings Call: Our Top 5 Analyst Questions

BioMarin’s first quarter saw revenue growth driven by continued demand for its enzyme therapies and Voxzogo, but the company missed Wall Street’s revenue and non-GAAP profit expectations. Management cited strong patient demand, especially... Full story

Yahoo Finance • 2 months ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More

Quick Read: Technologuy stocks helped lead the stock market higher on Friday, alongside a very positive April jobs report. First-quarter earnings have been outstanding, with 84% of reporting companies beating estimates. As we head into su... Full story

Yahoo Finance • 2 months ago

Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor

MENLO PARK, Calif., May 06, 2026--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor. Mr. Walbert brings more than three decades... Full story

Yahoo Finance • 2 months ago

BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is entering a "transition year" in 2026, prioritizing growth accelera PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting

VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia Researchers will presen... Full story

Yahoo Finance • 3 months ago

Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Rothschild & Co Redburn upgraded Snap... Full story

Yahoo Finance • 3 months ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 3 months ago

BioMarin Pharmaceutical Inc. (BMRN) Rated Overweight at Wells Fargo Despite Voxzogo Phase 2 Study Discontinuations

We recently compiled a list of the 10 Quality Value Stocks Likely to Make a Comeback According to Analysts. BioMarin Pharmaceutical Inc. is among the best value stocks to invest in. TheFly reported on March 16 that Wells Fargo maintained... Full story

Yahoo Finance • 4 months ago

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

On February 17, 2026, Boone Capital Management sold out its entire Cogent Biosciences(NASDAQ:COGT) stake, liquidating 945,042 shares previously worth $13.57 million. What happened According to an SEC filing dated February 17, 2026, Boone... Full story

Yahoo Finance • 4 months ago

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

On February 17, 2026, Boone Capital Management disclosed a new position in Tyra Biosciences(NASDAQ:TYRA), acquiring 398,482 shares worth $10.48 million at quarter’s end. What happened According to a Securities and Exchange Commission (SE... Full story

Yahoo Finance • 4 months ago

BioMarin Pharmaceutical (BMRN) Reports Positive Results From Ongoing Trials of VOXZOGO

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the Cheap Stocks to Buy for High Returns in 2026. On March 12, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released positive data from ongoing trials of VOXZOGO, which is the company’s ap... Full story

Yahoo Finance • 4 months ago

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

What happened According to a U.S. Securities and Exchange Commission (SEC) filing dated February 17, 2026, Boone Capital Management established a new position in HealthEquity by purchasing 212,856 shares. The reported value of the transac... Full story